As immigration raids have swept the country, it’s not just immigrants who have been kidnapped and detained. American citizens have also been caught up in the Trump administration’s draconian policies.

Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration ...

There are about 10+ Gigawatts per year of of AI data centers being built over the next 10+ years. Megapacks are proven in improving the energy quality that AI needs. This will be potentially $500 ...

The Brief keeps Texas voters and political observers up to speed on the most essential coverage of their elected officials, the policies that shape their daily lives and the future of our great state.

The Scattered Lapsus$ Hunters gang, which says it has stolen data from the Salesforce instances of dozens of international companies in recent months, upped its extortion game today by listing their ...

With the specter of more Salesforce breaches looming, Google — no stranger to such attacks — is advising organizations to step up their defenses against UNC6040. "This approach has proven particularly ...

Data centers are proliferating in Virginia and a blind man in Baltimore is suddenly contending with sharply higher power bills. The Maryland city is well over an hour’s drive from the northern ...

1. Erasmus MC Center of Expertise for Inherited Cardiovascular Diseases, Rotterdam, the Netherlands 2. Centre for Heart Muscle Disease, University College London (UCL), UK 3. Inherited Cardiovascular ...

Workday Rising 2025 opens with announcements of new AI agents for HCM and finance, but the big news is the new Workday Build developer platform and Data Cloud, along with consumption-based pricing.

MAPLE-HCM establishes Cytokinetics, Incorporated's aficamten as superior to metoprolol in obstructive HCM, reframing it as a potential first-line, best-in-class therapy. Commercial potential is ...

In one of two trials that substantially expand clinical evidence with myosin inhibitors in the treatment of hypertrophic cardiomyopathy (HCM), a next-in-class agent beat beta-blockers in first-line ...